Indian pharma companies lack the digital will: Indian Pharma Digital Health Report 2015
Advertisement
The report created by D Yellow Elephant analysed over 40 pharmaceutical companies, both domestic and multinational, in the country, to study their presence across 10 key digital parameters ranging across websites, applications and 10 major social media platforms
In a strong conclusive study by D Yellow Elephant, the pharma companies in India need to pull up their digital muscle to make healthcare accessible in all corners of India. The study titled the Indian Pharma Digital Health Report, evidently states that that only nine out of 40 -- less than 25 percent -- managed above 50 out of 100 on the studies parameters- the 10 key digital parameters ranging across websites, applications and 10 major social media platforms.
More specifically, the Indian pharma companies need to exploit the digital platforms to connect with the stakeholders. As compared to their international counterparts, the Indian companies are behind almost a time gap of 5-7 years, in reaching a digital milestone.
As for the popular social media platforms, the categorization and statistics for pharma companies is a clear view. LinkedIn is the most popular social media platform, but only 14 companies, barely 35 percent, were active on it. Google+, led by the professional gmail platform, is also preferred with 87 percent companies present on this platform. As far as India-specific Facebook is concerned, only eight out of 40, or 20 percent fell in this category, 12 had a Blogger presence, and other platforms like Slideshare, Instagram and Vine are used by less than 20 percent (as reported by IANS).
In a strong conclusive study by D Yellow Elephant, the pharma companies in India need to pull up their digital muscle to make healthcare accessible in all corners of India. The study titled the Indian Pharma Digital Health Report, evidently states that that only nine out of 40 -- less than 25 percent -- managed above 50 out of 100 on the studies parameters- the 10 key digital parameters ranging across websites, applications and 10 major social media platforms.
More specifically, the Indian pharma companies need to exploit the digital platforms to connect with the stakeholders. As compared to their international counterparts, the Indian companies are behind almost a time gap of 5-7 years, in reaching a digital milestone.
As for the popular social media platforms, the categorization and statistics for pharma companies is a clear view. LinkedIn is the most popular social media platform, but only 14 companies, barely 35 percent, were active on it. Google+, led by the professional gmail platform, is also preferred with 87 percent companies present on this platform. As far as India-specific Facebook is concerned, only eight out of 40, or 20 percent fell in this category, 12 had a Blogger presence, and other platforms like Slideshare, Instagram and Vine are used by less than 20 percent (as reported by IANS).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.